2011 Fiscal Year Final Research Report
Inactivated Sendai virus particles with an IL-2 gene exert anti-tumor effects on murine angiosarcoma
| Project/Area Number |
21791065
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
NISHIZAWA Aya 東京医科歯科大学, 大学院・医歯学総合研究科, 助教 (30431456)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | 遺伝子治療 / 免疫療法 / 血管肉腫 / HVJ-E / スニチニブリンゴ酸塩 / IL-2 |
|---|
| Research Abstract |
Cutaneous angiosarcoma is a malignant skin tumor with a high mortality rate despite the currently available therapeutic protocols.
Inactivated, replication-defective Sendai virus particles(HVJ-E) have been shown to have a powerful anti-tumor effect.
We aimed to establish a novel therapeutic tool for anigiosarcoma with HVJ-E, IL-2 gene, and/or sunitinib.
HVJ-E significantly inhibited tumor growth of angiosarcoma in vivo.
HVJ-E-containing murine IL-2 gene resulted in an even more significant inhibition of tumor growth than HVJ-E alone.
Anti-tumor effects of HVJ-E were associated with an increase of CD8(+) cells and NK cells, and a decrease of Tregs.
Sunitinib inhibits cell growth of ISOS-1 cells in vitro and in vivo.
The combination of the HVJ-E and Sunitinib resulted in an even more significant inhibition of tumor growth than HVJ-E alone.
|
